Regulatory Story
Go to market news section View chart   Print
Company Vectura Group plc
TIDM VEC
Headline

Director Declaration

Released 07:13 07-May-2013
Number 0287E07

RNS Number : 0287E
Vectura Group plc
07 May 2013
 



Vectura Group plc

Director Declaration

 

Chippenham, UK - 7 May 2013: In accordance with Listing Rule 9.6.14 (2) Vectura Group plc (LSE:VEC) announces that Anne Hyland, Chief Financial Officer and an executive Director of Vectura, has been appointed as a Non-Executive Director of Elementis plc with effect from 1 June, 2013.

 

Enquiries

 

Vectura Group plc

+44 (0)1249 667700

Chris Blackwell, Chief Executive


Karl Keegan, Corporate Development Director




FTI Consulting

+44 (0)20 7831 3113

John Dineen / Ben Atwell


 

About Vectura

Vectura Group plc develops inhaled therapies principally for the treatment of respiratory diseases. Vectura's main products target diseases such as asthma and chronic obstructive pulmonary disease (COPD), a growing market that is currently estimated to be worth in excess of $25bn.

 

Vectura has seven products marketed by its partners and a portfolio of drugs in clinical and pre-clinical development, a number of which have been licensed to major pharmaceutical companies. Vectura has development collaborations and licence agreements with several pharmaceutical companies, including Novartis, Sandoz (the generics arm of Novartis), Baxter and GlaxoSmithKline (GSK).

 

Vectura seeks to develop certain programmes itself where this will optimise value. Vectura's formulation and inhalation technologies are available to other pharmaceutical companies on an out-licensing basis where this complements Vectura's business strategy. For further information, please visit Vectura's website at www.vectura.com.

 

Forward-looking statements

This press release contains forward-looking statements, including statements about the discovery, development and commercialisation of products. Various risks may cause Vectura's actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programmes; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialisation activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDNFMGGKKFZGFZM
Close
London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.

Director Declaration - RNS